Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Apr 26;7(1):9.
doi: 10.1186/s41181-022-00162-3.

Highlight selection of radiochemistry and radiopharmacy developments by editorial board

Emerson Bernardes  1 , Peter Caravan  2 , R Michael van Dam  3 , Winnie Deuther-Conrad  4   5 , Beverley Ellis  6 , Shozo Furumoto  7 , Benjamin Guillet  8 , Ya-Yao Huang  9 , Hongmei Jia  10 , Peter Laverman  11 , Zijing Li  12 , Zhaofei Liu  13 , Filippo Lodi  14 , Yubin Miao  15 , Lars Perk  16 , Ralf Schirrmacher  11 , Johnny Vercoullie  17 , Hua Yang  18 , Min Yang  19 , Xing Yang  20 , Junbo Zhang  10 , Ming-Rong Zhang  21 , Hua Zhu  22
Affiliations
Review

Highlight selection of radiochemistry and radiopharmacy developments by editorial board

Emerson Bernardes et al. EJNMMI Radiopharm Chem. .

Abstract

Background: The Editorial Board of EJNMMI Radiopharmacy and Chemistry releases a biyearly highlight commentary to update the readership on trends in the field of radiopharmaceutical development.

Results: This commentary of highlights has resulted in 23 different topics selected by each member of the Editorial Board addressing a variety of aspects ranging from novel radiochemistry to first in man application of novel radiopharmaceuticals and also a contribution in relation to MRI-agents is included.

Conclusion: Trends in (radio)chemistry and radiopharmacy are highlighted demonstrating the progress in the research field being the scope of EJNMMI Radiopharmacy and Chemistry.

Keywords: Highlights; Radiochemistry; Radiopharmacy; Review.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they do not have competing interests.

Figures

Fig. 1
Fig. 1
Structures of 18F-labeled neopentyl glycol derivatives (A) and a scheme for radiosynthesis of 125I/211At-labeled neopentyl glycol derivatives (B)
Fig. 2
Fig. 2
Schematic illustration of the continuous-flow generation process of [18F]TfF (With permission from Zhou and Katzenellenbogen (2021) by Copyright Clearance Center’s Rightslink)
Fig. 3
Fig. 3
Schematic representation of in situ generation of [18F]Me4NF and subsequent aromatic fluorination
Fig. 4
Fig. 4
Chemical structure of fluorinated chelate with fluorine substituents in the pyridine rings
Fig. 5
Fig. 5
Chemical Structure of Ox-Fol-1 (green), 6R-RedFol-1 (blue), and 6S-RedFol-1 (red). Reproduced for Guzik et al
Fig. 6
Fig. 6
Chemical structure of [18F]5MEF and its application in myocardial bimodal imaging. Reprinted with permission from Journal of Medicinal Chemistry (J Med Chem 2022; 65: 497–506). Copyright © 2022 American Chemical Society
See this image and copyright information in PMC

References

    1. Abou DS, Thiele NA, Gutsche NT, Villmer A, Zhang H, Woods JJ, Baidoo KE, Escorcia FE, Wilson JJ, Thorek DLJ. Towards the stable chelation of radium for biomedical applications with an 18-membered macrocyclic ligand. Chem Sci. 2021;12:3733–3742. doi: 10.1039/D0SC06867E. - DOI - PMC - PubMed
    1. Archibald SJ, Allot L. The aluminium 18F fluorine revolution: simple radiochemistry with a big impact for radiolabelled biomolecules. EJNMMI Radiopharm Chem. 2021;6:30. doi: 10.1186/s41181-021-00141-0. - DOI - PMC - PubMed
    1. Chen M, Chen Z, Castillo JB, Cui L, Zhou K, Shen B, Xie J, Chin FT, Rao J. [18F]-C-SNAT4: an improved caspase-3-sensitive nanoaggregation PET tracer for imaging of tumor responses to chemo- and immunotherapies. EJNMMI. 2021;48:3386–3399. - PubMed
    1. Chen H, Zhao L, Ruan D, Pang Y, Hao B, Dai Y, et al. Usefulness of [68Ga]Ga-DOTA-FAPI-04 PET/CT in patients presenting with inconclusive [18F]FDG PET/CT findings. EJNMMI. 2021;48:73–86. - PubMed
    1. Cisternino S, Cazzola E, Skliarova H, Amico J, Malachini M, Gorgoni G, Anselmi-Tamburini U, Esposito J. Target manufacturing by Spark Plasma Sintering for efficient 89Zr production. Nucl Med Biol. 2022;104–105:38–46. doi: 10.1016/j.nucmedbio.2021.11.004. - DOI - PubMed